Global Drug Discovery Services Market

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY SERVICESMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY SERVICESMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TYPE:
5.1 Medicinal Chemistry
5.2 Biology Services
5.3 Drug Metabolism and Pharmacokinetics (DMPK)

6 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY PROCESS:
6.1 Target Selection
6.2 Target Validation
6.3 Hit-To-Lead Identification
6.4 Lead Optimization
6.5 Candidate Validation

7 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE:
7.1 Small Molecules
7.2 Biologics

8 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA:
8.1 Oncology
8.2 Neurology
8.3 Cardiovascular Diseases
8.4 Respiratory Diseases
8.5 Diabetes
8.6 Other Therapeutic Areas

9 GLOBAL DRUG DISCOVERY SERVICESMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL DRUG DISCOVERY SERVICESMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Thermo Fisher Scientific
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Merck
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 GE Healthcare
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Albany Molecular Research, Inc. (AMRI)
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Charles River Laboratories International
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Evotec
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 Pharmaceutical Product Development, LLC. (Ppd)
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Jubilant Biosys
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Covance
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Development

11.10 Genscript Biotech Corporation
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Development

11.11 Aurigene Discovery Technologies
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Development

11.12 Wuxi Apptec
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Development

11.13 Syngene
11.13.1 Overview
11.13.2 Financial Performance
11.13.3 Product Outlook
11.13.4 Key Development

12 Appendix
12.1 Related Reports